StreetInsider.com News Articles

BioElectronics Advances ActiPatch Commercial Rollout With Electrome

Wed, 17 Jun 2026 10:30:00 -0400

Strategic Agreement Enters Execution Phase as Electrome Prepares AI-Enabled Consumer Campaign for FDA-Cleared, Drug-Free Pain Relief Technology

JEFFERSON, MARYLAND - June 17, 2026 (NEWMEDIAWIRE) - BioElectronics Corporation ( https://www.bielcorp.com/) (OTC: BIEL), a developer of medical technology products, announces its strategic distribution and licensing agreement with Electrome Corporation has officially moved into the execution phase, and manufacturing is now underway for the launch of BioElectronics flagship pulsed shortwave therapy as part of the Electrome PAINKILLER platform.

The partnership marks a major milestone for both companies as Electrome prepares for an aggressive consumer launch strategy designed to accelerate awareness and

BioElectronics Advances ActiPatch Commercial Rollout With Electrome

Wed, 17 Jun 2026 10:30:00 -0400

Strategic Agreement Enters Execution Phase as Electrome Prepares AI-Enabled Consumer Campaign for FDA-Cleared, Drug-Free Pain Relief Technology

The partnership marks a major milestone for both companies as Electrome prepares for an aggressive consumer launch strategy designed to accelerate awareness and

BioElectronics Corporation's Chairman Updates Investors

Wed, 16 Oct 2024 08:45:00 -0400

Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma

FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Dear Shareholders,

It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant.

Current Medical (RecoveryRx) Sales

Although our RecoveryRx product is

BioElectronics Corporation's Chairman Updates Investors

Wed, 16 Oct 2024 08:45:00 -0400

Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma

FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Dear Shareholders,

It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant.

Current Medical (RecoveryRx) Sales

Although our RecoveryRx product is

BioElectronics Corporation's Chairman Updates Investors

Wed, 16 Oct 2024 08:45:00 -0400

Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma

FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Dear Shareholders,

It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant.

Current Medical (RecoveryRx) Sales

Although our RecoveryRx product is

BioElectronics Corporation's Chairman Updates Investors

Wed, 16 Oct 2024 08:45:00 -0400

Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma

FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Dear Shareholders,

It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant.

Current Medical (RecoveryRx) Sales

Although our RecoveryRx product is

BioElectronics Corporation's Chairman Updates Investors

Wed, 16 Oct 2024 08:45:00 -0400

Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma

FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Dear Shareholders,

It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant.

Current Medical (RecoveryRx) Sales

Although our RecoveryRx product is

BioElectronics Corporation's Chairman Updates Investors

Wed, 16 Oct 2024 08:45:00 -0400

Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma

FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Dear Shareholders,

It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant.

Current Medical (RecoveryRx) Sales

Although our RecoveryRx product is

BioElectronics Corporation's Chairman Updates Investors

Wed, 16 Oct 2024 08:45:00 -0400

Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma

FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Dear Shareholders,

It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant.

Current Medical (RecoveryRx) Sales

Although our RecoveryRx product is

BioElectronics Corporation's Chairman Updates Investors

Wed, 16 Oct 2024 08:45:00 -0400

Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma

FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Dear Shareholders,

It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant.

Current Medical (RecoveryRx) Sales

Although our RecoveryRx product is

BioElectronics Corporation's Chairman Updates Investors

Wed, 16 Oct 2024 08:45:00 -0400

Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma

FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Dear Shareholders,

It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant.

Current Medical (RecoveryRx) Sales

Although our RecoveryRx product is

BioElectronics Corporation's Chairman Updates Investors

Wed, 16 Oct 2024 08:45:00 -0400

Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma

FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Dear Shareholders,

It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant.

Current Medical (RecoveryRx) Sales

Although our RecoveryRx product is

BioElectronics Corporation's Chairman Updates Investors

Wed, 16 Oct 2024 08:45:00 -0400

Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma

FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Dear Shareholders,

It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant.

Current Medical (RecoveryRx) Sales

Although our RecoveryRx product is

BioElectronics Corporation's Chairman Updates Investors

Wed, 16 Oct 2024 08:45:00 -0400

Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma

FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

Dear Shareholders,

It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant.

Current Medical (RecoveryRx) Sales

Although our RecoveryRx product is

BioElectronics Corporation Announces Utility Patent Application Filing

Tue, 21 May 2024 08:09:00 -0400

Non-Invasive Device Addresses the Treatment of Chronic Inflammation
FREDERICK, MD - (NewMediaWire) - May 21, 2024 - BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the filing of a new USPTO utility patent application addressing the treatment of chronic inflammation. This patent application, numbered 18/667,971, was a collaborative effort of John Martinez, Kenneth McLeod, PhD, and Richard Staelin, PhD. It outlines methods, systems, apparatuses, and devices that modify the immune response through non-invasive stimulation of the vagal nerves. The application draws from the results of a recently completed double-blind, placebo-controlled, canine

BioElectronics Corporation Announces Utility Patent Application Filing

Tue, 21 May 2024 08:09:00 -0400

Non-Invasive Device Addresses the Treatment of Chronic Inflammation
FREDERICK, MD - (NewMediaWire) - May 21, 2024 - BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the filing of a new USPTO utility patent application addressing the treatment of chronic inflammation. This patent application, numbered 18/667,971, was a collaborative effort of John Martinez, Kenneth McLeod, PhD, and Richard Staelin, PhD. It outlines methods, systems, apparatuses, and devices that modify the immune response through non-invasive stimulation of the vagal nerves. The application draws from the results of a recently completed double-blind, placebo-controlled, canine

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study

Mon, 25 Mar 2024 08:45:00 -0400

96% of the Dogs Treated With the Active Model 088 Device Showed Marked Improvement

FREDERICK, MD, March 25, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) a developer of medical technology products, announces the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT)device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4%

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study

Mon, 25 Mar 2024 08:45:00 -0400

96% of the Dogs Treated With the Active Model 088 Device Showed Marked Improvement

FREDERICK, MD, March 25, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) a developer of medical technology products, announces the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT)device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4%

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study

Mon, 25 Mar 2024 08:45:00 -0400

96% of the Dogs Treated With the Active Model 088 Device Showed Marked Improvement

FREDERICK, MD, March 25, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) a developer of medical technology products, announces the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT)device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4%

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study

Mon, 25 Mar 2024 08:45:00 -0400

96% of the Dogs Treated With the Active Model 088 Device Showed Marked Improvement

FREDERICK, MD, March 25, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL) a developer of medical technology products, announces the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT)device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4%

BioElectronics Chairman Updates Investors

Thu, 15 Feb 2024 09:00:00 -0400

Discusses Clinical Trial Progress and Potential Legal Action Against MundiPharma

FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans. As I have mentioned many times, I believe our strategic

BioElectronics Chairman Updates Investors

Thu, 15 Feb 2024 09:00:00 -0400

Discusses Clinical Trial Progress and Potential Legal Action Against MundiPharma

FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans. As I have mentioned many times, I believe our strategic

BioElectronics Chairman Updates Investors

Thu, 15 Feb 2024 09:00:00 -0400

Discusses Clinical Trial Progress and Potential Legal Action Against MundiPharma

FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans. As I have mentioned many times, I believe our strategic

BioElectronics Chairman Updates Investors

Thu, 15 Feb 2024 09:00:00 -0400

Discusses Clinical Trial Progress and Potential Legal Action Against MundiPharma

FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans. As I have mentioned many times, I believe our strategic

BioElectronics Chairman Updates Investors

Thu, 15 Feb 2024 09:00:00 -0400

Discusses Clinical Trial Progress and Potential Legal Action Against MundiPharma

FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD.

The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans. As I have mentioned many times, I believe our strategic